SCHEMBL172595

SCHEMBL172595

CC(C)C[C@H](C)NCc1ccc(O)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.62
SIGMAR1 Q99720 2/20 0.48
ADRB2 P07550 7/20 0.44
MAPK1 P28482 5/20 0.44
CYP3A4 P08684 3/20 0.44
HSD17B10 Q99714 3/20 0.44
NPSR1 Q6W5P4 2/20 0.44
SLC6A2 P23975 2/20 0.44
ADRB1 P08588 2/20 0.44
ADRB3 P13945 2/20 0.44
CYP2D6 P10635 1/20 0.44
TSHR P16473 1/20 0.44
HIF1A Q16665 1/20 0.44
ADORA3 P0DMS8 1/20 0.44
PTGS1 P23219 1/20 0.44
HTR2A P28223 1/20 0.44
SLC6A4 P31645 1/20 0.44
MC4R P32245 1/20 0.44
ADRA1A P35348 1/20 0.44
OPRM1 P35372 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13995814 1.00 ALDH1A1 (0.62) ALDH1A1SIGMAR1ADRB2MAPK1CYP3A4
SCHEMBL13995981 0.82 ALDH1A1 (0.64) ALDH1A1SIGMAR1MAPK1HSD17B10TSHR
SCHEMBL13995946 0.81 ALDH1A1 (0.62) ALDH1A1SIGMAR1SLC6A2CYP2D6SLC6A3
SCHEMBL1516416 0.81 TAAR1 (0.47) ALDH1A1SIGMAR1MAPK1HSD17B10SLC6A2
SCHEMBL21799771 0.81 ALDH1A1 (0.62) ALDH1A1SIGMAR1
SCHEMBL13995689 0.81 ALDH1A1 (0.67) ALDH1A1SIGMAR1MAPK1TSHRTAAR1
SCHEMBL13995867 0.81 ALDH1A1 (0.67) ALDH1A1SIGMAR1MAPK1TSHRTAAR1
SCHEMBL13995974 0.81 ALDH1A1 (0.62) ALDH1A1SIGMAR1SLC6A2CYP2D6SLC6A3
SCHEMBL10005270 0.80 SIGMAR1 (0.79) SIGMAR1ADRB2MAPK1CYP3A4CYP2D6
SCHEMBL6186659 0.80 SIGMAR1 (0.79) SIGMAR1ADRB2MAPK1CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1255738-B1 GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO NEUROCRINE BIOSCIENCES INC (US) 2012-03-07 EP disclosed
US-7462625-B2 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto NEUROCRINE BIOSCIENCES, INC. (US) 2008-12-09 US disclosed
US-20070208049-A1 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto NEUROCRINE BIOSCIENCES, INC. (US) 2007-09-06 US disclosed
US-7179815-B2 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto NEUROCRINE BIOSCIENCES, INC. (US) 2007-02-20 US disclosed
US-7179815-B2 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto NEUROCRINE BIOSCIENCES, INC. (US) 2007-02-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208049-A1 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto GNRHR, GHRHR, LHCGR ALDH1A1 3443/4885SIGMAR1 392/4885ADRB2 571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.